Potential for biosimilars in rheumatology in Africa.
| Autor: | Abu-Zaid MH; Rheumatology and Rehabilitation, Tanta University Faculty of Medicine, Tanta, Egypt drmhassan113@yahoo.com., Adebajo A; Rheumatology and Health Services Research, The University of Sheffield, Sheffield, UK.; NIHR Sheffield Clinical Research Facility, Sheffield, UK., El Miedany Y; Rheumatology, Canterbury Christ Church College, Chatham, UK.; Rheumatology and Rehabilitation, Ain Shams University Faculty of Medicine, Cairo, Egypt. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Annals of the rheumatic diseases [Ann Rheum Dis] 2023 Dec; Vol. 82 (12), pp. 1508-1510. Date of Electronic Publication: 2023 Jul 19. |
| DOI: | 10.1136/ard-2023-224315 |
| Abstrakt: | Biosimilars are products which are highly similar to a reference biologic product (RBP). In Africa, regulatory frameworks for biosimilar approval are still in development in many countries and few biosimilars for rheumatic diseases are currently available. The use of biosimilar medicines in Africa provides an important opportunity to treat more rheumatology patients with biologic drugs. This editorial aims to shed a light on the potential benefits, challenges and current efforts, regarding the use of biosimilars in Africa in Rheumatology. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|